Welcome to the Stocktwits Top 25 Newsletter this week!

The Stocktwits Top 25 reports the 25 best-performing stocks in the S&P 500, Nasdaq 100, and Russell 2000 year to date and tracks their performances over time. To help you understand this data further, check out our FAQ page, and feel free to reach out if you have questions!

Bearish 🐻 | Bullish 🐮 | It’s Complicated 😵‍💫

Here are the Stocktwits Top 25 Lists for this week:

WhiteFiber has acquired two new sites in Yadkinville, North Carolina expanding it's footprint in the area. Each site, expected to come online in Q2 2027, will be commissioned with 30MW of gross utility capacity. Over time these sites have the potential to grow to 200MW of gross capacity.

With an experienced workforce that recently completed the development of flagship data center NC-1 in Madison, just 55 miles from Yadkinville, WhiteFiber is poised to launch these locations while also adding the second tranche of power to NC-1, bringing that site to 99MW of gross capacity.

By Q2 2027 WhiteFiber will be operating 159 gross MW near the Piedmont Triad. The WhiteFiber flywheel has started spinning and momentum is building.

3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here.

Moderna’s +129% week lit the biotech fuse, while one reverse split scrambled the Russell scoreboard.

$MRNA ( ▲ 8.86% ) : Moderna, the market-wide lead-in: Shares jumped +129% this week after the melanoma vaccine it developed with Merck met both Phase 3 endpoints. Wednesday’s +177% surge partially unwound, but Friday added +9%. Risk: Moderna hasn’t disclosed the treatment effect, and full results remain pending.

$ATEX ( ▲ 9.31% ) : Anterix, this week’s top dawg after jumping from #23 to #7: Shares gained +9% as investors revisited its utility-spectrum pipeline and SpaceX-related optionality. The company had $33.1M of contracted proceeds outstanding at quarter-end, but revenue was only $2M. Risk: Monetization still depends on closing lumpy spectrum deals.

$SLS ( ▲ 15.37% ) : Sellas Life Sciences, new at #8: Shares ran +15% as Moderna’s cancer-vaccine result reignited retail interest in immuno-oncology. Sellas still hasn’t released final REGAL Phase 3 data. Risk: The AML trial’s final analysis is binary and triggers at 80 deaths; only 78 were reported as of May 11.

$BYND ( ▲ 2.0% ) : Beyond Meat, new at #1: The screen showed +1,701% YTD, but that figure is a 1-for-30 reverse-split mirage, not an investable return. Q2 sales fell to $68.8M, while adjusted EBITDA remained a $27.7M loss. Risk: Weak demand, cash burn, and debt still overwhelm the chart.

$AEHR ( ▼ 4.0% ) : Aehr Test Systems, climbed from #5 to #4 despite a -4% week: Momentum cracked after a fourfold YTD run, even with $100.6M of effective backlog and another silicon-photonics production order. Risk: The order ships in early 2027, while the roughly 25x forward-sales multiple leaves little room for delays.

Next week’s swing factor: Nvidia reports Aug. 26. Its AI demand commentary will test Aehr, MaxLinear, Applied Optoelectronics, and Ichor.

Want to see some change? Email me, Kevin Travers, with feedback, and follow me on Stocktwits. Send me charts and ideas! Refer a friend for this quarter’s edition of The RIP Forecast 😎

Securities Disclaimer: STOCKTWITS IS NOT A TAX ADVISOR, BROKER, FINANCIAL ADVISOR OR INVESTMENT ADVISOR. THE SERVICE IS NOT INTENDED TO PROVIDE TAX, LEGAL, FINANCIAL OR INVESTMENT ADVICE, AND NOTHING ON THE SERVICE SHOULD BE CONSTRUED AS AN OFFER TO SELL, A SOLICITATION OF AN OFFER TO BUY, OR A RECOMMENDATION FOR ANY SECURITY. Trading in such securities can result in immediate and substantial losses of the capital invested. You should only invest risk capital, and not capital required for other purposes. You alone are solely responsible for determining whether any investment, security or strategy, or any other product or service, is appropriate or suitable for you based on your investment objectives and personal and financial situation. You should also consult an attorney or tax professional regarding your specific legal or tax situation. The Content is to be used for informational and entertainment purposes only and the Service does not provide investment advice for any individual. Stocktwits, its affiliates and partners specifically disclaim any and all liability or loss arising out of any action taken in reliance on Content, including but not limited to market value or other loss on the sale or purchase of any company, property, product, service, security, instrument, or any other matter. You understand that an investment in any security is subject to a number of risks, and that discussions of any security published on the Service will not contain a list or description of relevant risk factors. In addition, please note that some of the stocks about which Content is published on the Service have a low market capitalization and/or insufficient public float. Such stocks are subject to more risk than stocks of larger companies, including greater volatility, lower liquidity and less publicly available information. Read the full terms & conditions here. 🔍

Author Disclosure: The author of this newsletter does not hold positions in any of the securities or assets mentioned. 📋